All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The results of an open-label, multicenter phase II trial on the use of entospletinib in indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL) were recently published in the British Journal of Haematology, by David Andorsky from the Rocky Mountain Cancer Centers, CO, USA, and colleagues.
Entospletinib (GS-9973) is a competitive inhibitor of the spleen tyrosine kinase (Syk). Syk is actively involved in the B-cell receptor (BCR) signalling pathway as it is believed to act upstream of both the Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K). Syk has been associated with lymphoma cell survival and proliferation in many B-cell malignancies and thus provides a great pharmacological target. The aim of this phase II trial (NCT01799889) was to assess the efficacy and tolerability of entospletinib in relapsed or refractory (R/R) iNHL or MCL patients. The primary endpoint of the study was progression-free survival (PFS), as assessed by an independent review committee (IRC). Key secondary endpoints included safety and overall response rate (ORR).
The results of this phase II trial indicate that entospletinib monotherapy leads to low response rates in R/R iNHL and MCL patients, despite its tolerable profile. The investigators proposed that entospletinib should be investigated in combination with other pharmacological agents in patients with hematological malignancies.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox